Abstract:BACKGROUND: Esophageal squamous cell carcinoma (ESCC), the predominant type of esophageal cancer, has a 5-year survival rate less than 20%. Although the cause of poor prognosis is the high incidence and mortality of ESCC, the high rate of metastasis after esophageal cancer surgery is the main cause of death after the surgery. Bromodomain-containing protein 4 (BRD4), an epigenetic reader of chromatin-acetylated histones in tumorigenesis and development, plays an essential role in regulating oncogene expression. BRD4 inhibition and BRD4 inhibition-based treatment can potentially suppress ESCC growth. However, the effects and mechanisms of action of BRD4 on ESCC cell migration remain unclear.AIM: To explore the effect of BRD4 on cell migration of ESCC <i>in vitro</i> and its possible molecular mechanism.METHODS: Human ESCC cell lines KYSE-450 and KYSE-150 were used. The 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide assay was performed to examine cell proliferation, and the transwell migration assay was conducted to test ESCC cell migration. JQ1, a BRD4 inhibitor, was applied to cells, and BRD4 siRNA was transfected into ESCC cells to knockdown endogenous BRD4. GFP-RFP-LC3 adenovirus was infected into ESCC cells to evaluate the effect of JQ1 on autophagy. Western blotting was performed to determine the protein levels of BRD4, E-cadherin, vimentin, AMP-activated protein kinase (AMPK), and p-AMPK.RESULTS: BRD4 was either downregulated by small interfering RNA or pretreated with JQ1 in ESCC cells, leading to increased tumor migration in ESCC cells in a dose- and time-dependent manner. Inhibition of BRD4 not only significantly suppressed cell proliferation but also strongly increased cell migration by inducing epithelial-mesenchymal transition (EMT). The protein expression of vimentin was increased and E-cadherin decreased in a dose-dependent manner, subsequently promoting autophagy in KYSE-450 and KYSE-150 cells. Pretreatment with JQ1, a BRD4 inhibitor, inhibited BRD4-induced LC3-II activation and upregulated AMPK phosphorylation in a dose-dependent manner. Additionally, an increased number of autophagosomes and autolysosomes were observed in JQ1-treated ESCC cells. The autophagy inhibitor 3-methyladenine (3-MA) reversed the effects of BRD4 knockdown on ESCC cell migration and blocked JQ1-induced cell migration. 3-MA also downregulated the expression of vimentin and upregulation E-cadherin.CONCLUSION: BRD4 inhibition enhances cell migration by inducing EMT and autophagy in ESCC cells <i>via</i> the AMPK-modified pathway. Thus, the facilitating role on ESCC cell migration should be considered for BRD4 inhibitor clinical application to ESCC patients.

The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer

JQ1: a novel potential therapeutic target.

The BRD4 Inhibitor JQ1 Augments the Antitumor Efficacy of Abemaciclib in Preclinical Models of Gastric Carcinoma

JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer*

Igfbp-Rp1 Acts As A Potential Tumor Suppressor Via the Suppression of Erk Signaling Pathway in Endometrial Cancer Cells

Effects of BRD4 inhibitor JQ1 on the expression profile of super-enhancer related lncRNAs and mRNAs in cervical cancer HeLa cells

RBPJ Inhibits the Movability of Endometrial Carcinoma Cells by Mir-155/Nf-κb/ros Pathway

JQ1 suppresses cell proliferation and induces apoptosis in bladder cancer

BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2/NID1 signaling

BET Bromodomain Inhibition Potentiates Ocular Melanoma Therapy by Inducing Cell Cycle Arrest

Programmed Cell Death-1 Inhibitor Combination Treatment for Recurrent Proficient Mismatch Repair/ Miscrosatellite-Stable Type Endometrial Cancer: A Case Report.

BRD4 inhibitor JQ1 may affect the prognosis of cervical cancer through super-enhancer-related genes

BRD4 Inhibition Sensitizes Cervical Cancer to Radiotherapy by Attenuating DNA Repair.

Therapeutic Targeting of BRD4 in Head Neck Squamous Cell Carcinoma

Inhibition of bromodomain-containing protein 4 enhances the migration of esophageal squamous cell carcinoma cells by inducing cell autophagy

Combinational Therapeutic Targeting of BRD4 and CDK7 Synergistically Induces Anticancer Effects in Head and Neck Squamous Cell Carcinoma

JQ1, a Small Molecule Inhibitor of BRD4, Suppresses Cell Growth and Invasion in Oral Squamous Cell Carcinoma

BRD4 drives esophageal squamous cell carcinoma growth by promoting RCC2 expression

BRD4 Inhibition by AZD5153 Promotes Antitumor Immunity Via Depolarizing M2 Macrophages

Bromodomain and Extraterminal (BET) Protein Inhibition Suppresses Tumor Progression and Inhibits HGF-MET Signaling Through Targeting Cancer-Associated Fibroblasts in Colorectal Cancer.

Targeting C-Myc: JQ1 As a Promising Option for C-Myc-amplified Esophageal Squamous Cell Carcinoma.